957P Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on toxicity and immune therapy

F Cortiula,L Hendriks,R Wijsman,S Debakker,M Steens,S.T Peeters,A Michelotti,N.M Sijtsema,S Urban,A Niezink,S Dursun,G Bootsma,R Canters,F Tohidinezhad,G Fasola,I Rinaldi,V Taasti,R Houben,D De Ruysscher

doi:10.1016/j.annonc.2022.07.1083

957P Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on toxicity and immune therapy

F Cortiula, L Hendriks + Show 17 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1083

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Ospedale Santa Maria della Misericordia di Udine, Maastricht University Medical Centre, University Medical Center Groningen, Zuyderland Medisch Centrum, University of Udine, Maastro Clinic, Maastricht University

#Intensity Modulated Proton Therapy #Concurrent Chemotherapy In Stage + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Concurrent chemo-radiotherapy (CCRT) followed by adjuvant durvalumab (D) represents standard of care for fit patients (pts) with unresectable stage III NSCLC. Aim: assess whether intensity modulated proton therapy (IMPT), compared to intensity modulated photon therapy (IMRT) can reduce lymphopenia (primary endpoint), and other toxicities; and whether IMPT affects immune related adverse events (irAEs) incidence.

Full Text